Exhibit 4.9



AMENDMENT # 3









THE SYMBOL
"[****]" DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMIITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION



AMENDMENT
TO THE MASTER SERVICE AGREEMENT FOR REDHILL BIOPHARMA LTD.’S RHB R&D PROGRAM














|BY AND BETWEEN: | RedHill Biopharma Ltd., with principle place of business at21 Ha’arba’a St. Tel-Aviv 64739, Israel(herein referred to as the “Client”),                                                                                                                                                          
|--------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|                |                                                                                                                                                                                                                                                                                                  
|                |                                                                                                                                                                                                                                                                                                  
|AND:            | 7810962 Canada Inc (doing Business under the name “InSymbiosis”), a body politic and corporate, duly incorporated according to the laws of Canada and with principle place of business at 245 Victoria Ave, Suite 100, Montreal, Quebec, H3Z 2M6, Canada, (herein referred to as the “Provider”),







The
Client and the Provider are, in this Agreement, sometimes individually referred to as “Party” and collectively as
the “Parties”.



WHEREASon 28 April 2011,the Client and the Provider entered into a Master Service Agreement in relation to the Client’s
RHB R&D Program (the “MSA”);



WHEREASWHEREAS the MSA was scheduled to terminate on April 28, 2015 as per amendment 2 and the parties hereby agree to formally extend
the term of the MSA until April 28, 2016 (the "Extended Period"); and



WHEREASthe Parties have agreed to certain terms and conditions, the whole as is fully set forth below.





NOW,
THEREFORE, THE PARTIES HERETO AGREE AS FOLLOWS:



| | 1. | Unless
                                         specifically set out otherwise in this agreement (the “AMENDMENT AGREEMENT”),
                                         the terms of the MSA shall continue to apply.
| | -- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 2. | The
                                         parties hereby agree to formally extend the term of the MSA until April 28, 2016.
| | -- | ------------------------------------------------------------------------------------------------------------------------------



| | 3. | During
                                         the term of the Agreement, PROVIDER will charge CLIENT a monthly project management fee
                                         of $US [****]. This monthly project management fee
                                         will be payable each quarter, in advance, upon lawful invoice to be provided by the PROVIDER
                                         to the CLIENT within 21 days of the beginning of the relevant quarter according to the
                                         following payment schedule:
| | -- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------





7810962 Canada Inc


CONFIDENTIAL2








|• | Payment 1: May 2015 to July 2015         
|- | -----------------------------------------
|• | Payment 2:  August 2015 to October 2015  
|• | Payment 3:  November 2015 to January 2015
|• | Payment 4:  February 2015 to April 2016  







IN
WITNESS WHEREOF, the parties hereto have executed this Amendment Agreement as of the date first herein above mentioned.







REDHILL
BIOPHARMA Ltd.









|/s/ Dror Ben-Asher       |  | /s/ Ori Shilo                     | 
|------------------------ |  | --------------------------------- | 
|Per:      Dror Ben-Asher |  | Per:     Ori Shilo                | 
|Title:    CEO            |  | Title:   VP Finance and Operation
|Date:    May 21, 2015    |  | Date:   May 21, 2015              | 









PARTY
OF THE FIRST PART





7810962
Canada Inc.





Per:     Alain
Guimond

Title:
  Senior Director of R&D

Date:   12May2015





PARTY
OF THE SECOND PART











7810962 Canada Inc